Root (ROOT)
(Delayed Data from NSDQ)
$80.97 USD
+4.86 (6.39%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $80.12 -0.85 (-1.05%) 7:42 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.97 USD
+4.86 (6.39%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $80.12 -0.85 (-1.05%) 7:42 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum D VGM
Zacks News
Reasons Why Investors Should Retain Sun Life (SLF) Stock Now
by Zacks Equity Research
Sun Life Financial (SLF) is well-poised to gain from strategic buyouts, higher large-case group benefits sales, business growth, prudent capital deployment and sufficient liquidity.
Everest Re (RE) Rallies 22% YTD: Can It Retain the Momentum?
by Zacks Equity Research
New business growth, strong renewal retention, continued favorable rate increases and a solid capital position continue to drive Everest Re (RE).
Is it Time to Add Argo Group (ARGO) Stock to Your Portfolio?
by Zacks Equity Research
Highly profitable business, growth efforts, expense initiative program, investment in technology and a solid capital position poise Argo Group (ARGO) for growth.
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
by Zacks Equity Research
Clovis Oncology, NiSource, DocuSign, Root and Endava are part of the Zacks Screen of the Week article.
Should You Hold Manulife Financial (MFC) in Your Portfolio?
by Zacks Equity Research
Manulife Financial (MFC) stands to gain from in-force business growth in Canada and Asia, strategic buyouts, robust capital position and effective capital deployment.
Bet on 5 Top Stocks With Rising P/E
by Sanghamitra Saha
Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).
Here's Why You Should Hold Brighthouse Financial (BHF) Stock
by Zacks Equity Research
Brighthouse (BHF) is well poised for growth on the back of higher alternative investment income, well diversified, high-quality portfolio and solid performances by the Annuities, Life and Run-off segments.
Should You Retain Axis Capital (AXS) Stock in Your Portfolio?
by Zacks Equity Research
Increases in lines of business, new business growth, continued strong retentions, accelerated digitalization and prudent capital deployment continue to drive AXIS Capital (AXS).
Here's Why Radian Group (RDN) Stock is an Attractive Bet Now
by Zacks Equity Research
Radian Group (RDN) is poised to grow due to well-performing real estate services and valuation products, favorable growth estimates and effective capital deployment.
Here's Why You Should Retain RLI Stock in Your Portfolio
by Zacks Equity Research
RLI stands to gain from compelling product portfolio, sustained rate increase, expanded distribution and operational strength and sufficient liquidity.
Why Should You Stay Invested in Arch Capital (ACGL) Stock?
by Zacks Equity Research
New business opportunities, rate increases, growth in existing accounts and solid capital position poise Arch Capital (ACGL) for growth
Progressive (PGR) November Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Progressive's (PGR) November earnings reflect higher revenues, partially offset by higher expenses.
Unum Group (UNM) Up 63.6% in a Year: More Room to Run?
by Zacks Equity Research
Unum Group (UNM) stock rallies on the back of higher sales, higher persistency, improving premium income and prudent capital deployment.
Travelers (TRV) Up 15.2% in a Year: More Room for Growth?
by Zacks Equity Research
Travelers (TRV) stock rallies on the back of higher average levels of invested assets, positive renewal premium change and effective capital deployment.
Kinsale (KNSL) Up 28.9% in a Year: Can It Maintain the Upside?
by Zacks Equity Research
Kinsale (KNSL) stock rallies on the back of technology-driven low-cost operation, strong premium growth, higher net-earned premiums and effective capital deployment.
Progressive (PGR) Stock Up 25% YTD: Will the Bull Run Continue?
by Zacks Equity Research
An attractive product portfolio, leadership position, strength in Vehicle and Property businesses, healthy policies in force, retention and solid capital position continue to drive Progressive (PGR).
Should You Retain CNA Financial (CNA) in Your Portfolio?
by Zacks Equity Research
CNA Financial (CNA) is poised to grow on improved current accident year underwriting results and growth in invested asset base and sufficient liquidity.
Why You Should Add Employers Holdings (EIG) to Your Portfolio
by Zacks Equity Research
Niche focus on low-to-medium hazard risk small businesses, better pricing, investment in technology, solid capital position and effective capital deployment poise Employers Holdings (EIG) for growth.
Here's Why Investors May Consider Betting on W.R. Berkley (WRB)
by Zacks Equity Research
W.R. Berkley (WRB) is poised to benefit from higher premiums, growing underwriting profits, reductions in loss ratio and effective capital deployment.
Reasons Why Investors Should Retain NMI Holdings (NMIH)
by Zacks Equity Research
NMI Holdings (NMIH) is well-poised for growth owing to the increasing size of the U.S. mortgage insurance market, expansion of customer franchise and a well-performing reinsurance market.
Arthur J. Gallagher (AJG) Up 18% YTD: More Upside Left?
by Zacks Equity Research
Strong-performing Brokerage and Risk Management segments, strategic buyouts to capitalize on growing market opportunities and effective capital deployment poise Arthur J. Gallagher (AJG) for growth.
Why Should You Stay Invested in Argo Group (ARGO) Stock?
by Zacks Equity Research
Argo Group (ARGO) is set to grow banking on the strength of highly profitable business, growth efforts, expense initiative program, investment in technology and a solid capital position.
Here's Why You Should Retain Markel (MKL) in Your Portfolio
by Zacks Equity Research
Markel (MKL) is well poised to gain from favorable rates, growth across all its product lines, higher earned premiums and prudent capital deployment.
Here's Why Investors Should Hold Onto Voya Financial (VOYA)
by Zacks Equity Research
Voya Financial (VOYA) is poised to benefit from strategic acquisitions, higher underwriting results, improved investment income and strong financial standing.
How Much Upside is Left in Root, Inc. (ROOT)? Wall Street Analysts Think 113%
by Zacks Equity Research
The consensus price target hints at an 113.2% upside potential for Root, Inc. (ROOT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.